Gleevec Wins Regular Approval as GIST Adjuvant

WASHINGTON (MedPage Today) — The provisional approval of imatinib (Gleevec) as adjuvant therapy for a certain form of gastrointestinal stromal tumor has been made permanent, the FDA announced.

Post a Comment

Comments are closed.